Literature DB >> 33236521

Fibrous bands associated with higher Masaoka stage and poor recurrence-free survival in patients with thymoma.

Kazuhiro Minami1, Naoe Jimbo2, Yugo Tanaka1, Takahiro Uchida1, Takeshi Okamoto1, Nahoko Shimizu1, Takefumi Doi1, Daisuke Hokka1, Tomoo Itoh2, Yoshimasa Maniwa1.   

Abstract

BACKGROUND: Fibrous bands (FBs) are one of the histological features in tumors which can be confirmed by hematoxylin and eosin (H&E)-stained slides. FBs have been reported to correlate with malignancy in various tumors. This study aimed to investigate whether the presence of FBs is associated with malignancy in thymoma.
METHODS: A total of 123 consecutive patients with thymoma who underwent microscopically complete resections from January 2000 to December 2018 were enrolled into this study. H&E-stained slides of all thymoma patients were re-examined. Study patients were classified into two groups: with FBs (n = 36) and without FBs (n = 87). Clinicopathological characteristics, overall survival (OS), and recurrence-free survival (RFS) were compared between the two groups. Furthermore, multivariate analyses were performed to identify whether the presence of FBs was associated with higher Masaoka stage and poor prognosis in patients with thymoma.
RESULTS: The Masaoka stage was found to be higher and recurrence more likely in thymoma patients with FBs than in those without. RFS was significantly poorer in thymoma patients with FBs than in those without, although no significant difference was observed in OS between them. The presence of FBs was significantly associated with higher Masaoka stage in the multivariate analysis using logistic regression. Additionally, the presence of FBs was an independent prognostic factor for poor RFS in multivariate analysis using Cox's proportional hazards model.
CONCLUSIONS: The presence of FBs in patients with thymoma was associated with higher Masaoka stage, higher recurrence rate, and poorer RFS. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Fibrous bands (FBs) are bands of fibrosis dividing tumors into different-sized irregular islands. The presence of FBs is associated with higher Masaoka stage and poor recurrence-free survival in patients with thymoma. WHAT THIS STUDY ADDS: The presence of fibrous bands might be associated with the malignant behavior of thymoma. Confirming the presence or absence of FBs may result in personalized medication for patients with thymoma.
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Fibrous bands; Masaoka stage; hematoxylin and eosin-stained slide; recurrence-free survival; thymoma

Year:  2020        PMID: 33236521      PMCID: PMC7862782          DOI: 10.1111/1759-7714.13755

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  39 in total

1.  Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer.

Authors:  H Breuninger; G Schaumburg-Lever; J Holzschuh; H P Horny
Journal:  Cancer       Date:  1997-03-01       Impact factor: 6.860

Review 2.  A review of prognostic factors in thymic malignancies.

Authors:  Frank Detterbeck; Samuel Youssef; Enrico Ruffini; Meinoshin Okumura
Journal:  J Thorac Oncol       Date:  2011-07       Impact factor: 15.609

3.  Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.

Authors:  Akira Orimo; Piyush B Gupta; Dennis C Sgroi; Fernando Arenzana-Seisdedos; Thierry Delaunay; Rizwan Naeem; Vincent J Carey; Andrea L Richardson; Robert A Weinberg
Journal:  Cell       Date:  2005-05-06       Impact factor: 41.582

4.  Fibrous stroma is associated with poorer prognosis in lung squamous cell carcinoma patients.

Authors:  Yusuke Takahashi; Genichiro Ishii; Tetsuhiko Taira; Satoshi Fujii; Shinya Yanagi; Tomoyuki Hishida; Junji Yoshida; Mitsuyo Nishimura; Hiroaki Nomori; Kanji Nagai; Atsushi Ochiai
Journal:  J Thorac Oncol       Date:  2011-09       Impact factor: 15.609

5.  Prognosis of thymic epithelial tumors according to the new World Health Organization histologic classification.

Authors:  Moo Suk Park; Kyung Young Chung; Kil Dong Kim; Woo Ick Yang; Jae Ho Chung; Young Sam Kim; Joon Chang; Joo Hang Kim; Sung Kyu Kim; Se Kyu Kim
Journal:  Ann Thorac Surg       Date:  2004-09       Impact factor: 4.330

6.  Thymoma: a multivariate analysis of factors predicting survival.

Authors:  D Blumberg; J L Port; B Weksler; R Delgado; J Rosai; M S Bains; R J Ginsberg; N Martini; P M McCormack; V Rusch
Journal:  Ann Thorac Surg       Date:  1995-10       Impact factor: 4.330

7.  Histological categorisation of fibrotic cancer stroma in advanced rectal cancer.

Authors:  H Ueno; A M Jones; K H Wilkinson; J R Jass; I C Talbot
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

8.  Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer.

Authors:  Alex Soltermann; Verena Tischler; Stefanie Arbogast; Julia Braun; Nicole Probst-Hensch; Walter Weder; Holger Moch; Glen Kristiansen
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

Review 9.  Stromal fibroblasts in cancer initiation and progression.

Authors:  Neil A Bhowmick; Eric G Neilson; Harold L Moses
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

10.  The impact of thymoma histotype on prognosis in a worldwide database.

Authors:  Cleo-Aron Weis; Xiaopan Yao; Yanhong Deng; Frank C Detterbeck; Mirella Marino; Andrew G Nicholson; James Huang; Philipp Ströbel; Alberto Antonicelli; Alexander Marx
Journal:  J Thorac Oncol       Date:  2015-02       Impact factor: 20.121

View more
  1 in total

1.  The Studies of Prognostic Factors and the Genetic Polymorphism of Methylenetetrahydrofolate Reductase C667T in Thymic Epithelial Tumors.

Authors:  Miaolong Yan; Jiayuan Wu; Min Xue; Juanfen Mo; Li Zheng; Jun Zhang; Zhenzhen Gao; Yi Bao
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.